As per the research report, the size of the Asia Pacific Ulcerative Colitis Market is valued at USD 0.85 billion in 2019 and is projected to grow at a CAGR of 7.9%, to reach USD 1.25 billion by 2024 during the forecast period 2019-2024.
Ulcerative Colitis is an inflammatory bowel disease that results in ulcers and inflammation of the rectum and colon. The disease usually lasts long term and the symptoms include diarrhea with blood and abdominal pain. It can also result in inflammations in several body parts and can also lead to colon cancer.
The causes for the disease include genetics, dysfunction of immune system and some other factors. Endoscopy through the rectum is one of the best diagnostic options for ulcerative colitis. There are numerous medications available for the disease ranging from drugs to surgery. The risk of fatalities in patients with the disease is very low.
Due to the changing lifestyles of people with unhealthy diets, prevalence of ulcerative colitis has increased. Increase in investments in pharmaceutical industries for the development of novel drugs, growing risk of acquiring colon cancer and growing healthcare expenditure are expected to propel the market growth. However, strict regulations on product approvals especially biosimilars and chances of recurrence of the disease are hindering the market growth.
This research report segmented and sub-segmented into the following categories:
Proctosigmoiditis is the most common type of ulcerative colitis and hence it holds the major market share.
Asia Pacific is expected to be the fastest growing market. It is due to the developing healthcare sector in emerging countries such as India through government intervention and expansions of major pharmaceutical companies to this region.
The Top companies leading in the APAC Ulcerative Colitis Market profiled in the report are Abbott Laboratories, GlaxoSmithKline, Pfizer, Takeda Pharmaceuticals, AbbVie, Johnson and Johnson, Merck, Sanofi, F. Hoffmann-La Roche and Shire Pharmaceuticals.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Monoclonal Antibodies
5.1.2.1 Humira
5.1.2.2 Simponi
5.1.2.3 Remicade
5.1.2.4 Entyvio
5.1.3 Biosimilars
5.1.4 Pharmaceuticals
5.1.4.1 Mesalamine
5.1.4.1.1 Asacol HD
5.1.4.1.2 Pentasa
5.1.4.1.3 Lialda
5.1.4.1.4 sfRowasa
5.1.4.2 Balsazide
5.1.4.2.1 Colazal
5.1.4.2.2 Giazo
5.1.4.3 Budesonide
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Type
5.2.1 Introduction
5.2.2 Proctosigmoiditis
5.2.3 Ulcerative Proctitis
5.2.4 Pancolitis
5.2.5 Left-sided Colitis
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Route of Administration
5.3.1 Introduction
5.3.2 Oral
5.3.3 Injectable
5.3.4 Y-o-Y Growth Analysis, By Route of Administration
5.3.5 Market Attractiveness Analysis, By Route of Administration
5.3.6 Market Share Analysis, By Route of Administration
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By Route of Administration
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By Route of Administration
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By Route of Administration
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GlaxoSmithKline
8.3 Pfizer
8.4 Takeda Pharmaceuticals
8.5 AbbVie
8.6 Johnson and Johnson
8.7 Merck
8.8 Sanofi
8.9 F. Hoffmann-La Roche
8.10 Shire Pharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
